First Patient Dosed in Eye Aging Reversal Trial
TL;DR Summary
Life Biosciences has dosed the first patient in an FDA-cleared trial of ER-100, a gene-therapy approach to reverse age-related degeneration of retinal neurons in glaucoma by reprogramming cells with Yamanaka factors activated by doxycycline for eight weeks. The work, building on Harvard's David Sinclair research, aims to rejuvenate vision but faces expert caution about potential runaway cell growth or cancer from cellular reprogramming.
- First Human Receives Experimental Therapy to Reverse Cellular Aging Gizmodo
- The first-ever reverse-aging drug was just injected into a human Business Insider
- Re-Setting the Epigenetic Clock To Reverse Cellular Aging Technology Networks
- This Biotech Startup Thinks It Can Reverse Vision Loss and Cellular Aging. It's Testing a Novel Therapy Now inc.com
- Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss WIRED
Reading Insights
Total Reads
0
Unique Readers
24
Time Saved
16 min
vs 17 min read
Condensed
98%
3,357 → 63 words
Want the full story? Read the original article
Read on Gizmodo